Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) |
| 26 Sept 2025 |
| 80,802 Orion Corporation A shares converted into B shares | 19 Sept 2025 |
| 337,000 Orion Corporation A shares converted into B shares | 20 Aug 2025 |
| Orion Corporation: Managers' transactions - Juhani Kankaanpää | 8 Aug 2025 |
| Orion Corporation: Managers' transactions - Satu Ahomäki | 4 Aug 2025 |